Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04781634 | a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL | PHASE1 | RECRUITING | 40 | — | — | Mar 7, 2021 | Jul 1, 2027 | Feb 25, 2025 | 1 | China |
Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)
The response rate of CD19 and CD22 prime CAR-T treatment will be recorded and assessed according to the National Comprehensive Cancer Network Guideline
| Arm | Type | Description |
|---|---|---|
| prime CAR- T cells | EXPERIMENTAL | Patients will be be treated with CD19 and CD22 prime CAR- T cells |
| Name | Type | Description |
|---|---|---|
| CD19 and CD22 targeted prime CAR-T cells | BIOLOGICAL | A single infusion of CD19 and CD22 prime CAR-T cells will be administered intravenously |
Inclusion Criteria: 1. Signed written informed consent 2. Diagnose as Relapsed and Refractory B -ALL, and meet one of the following conditions: 1. Failed to standard chemotherapy regimens; 2. Relapse after complete remission, high-risk and / or refractory patients ; 3. Relapse after hemat...